PDCD1 and hepatocellular carcinoma: Despite the remarkable efficacy of ICIs in HCC treatment, primary resistance to PD-1/PD-L1 blockade remains a significant challenge, with clinical benefit limited to only 15-20% of HCC patients (79–81).